Oculis is a biopharmaceutical company purposefully driven to save sight & improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. Headquartered in Switzerland, Oculis’ goal is to deliver life-changing treatments to patients worldwide.

Products, services, technology

OCS-01 being developed in DME and Inflammation and Pain following ocular surgery
OCS-02 being developed for Dry Eye Disease and Uveitis
OCS-05 being developed for neuro-ophthalmic diseases
Pre-clinical candidates for retinal disorders and for ocular inflammation

Location
Canton
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    10-19
Key business

You may also be interested in